Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
Numerous reports have associated atypical antipsychotic agents with hyperglycemia, diabetes mellitus, and diabetic ketoacidosis. Although the mechanisms are poorly understood, clinical experience suggests that these adverse effects are major areas of concern and require attention by the psychiatric team and primary care clinicians. This article discusses my clinical experience with glucose metabolism impairment related to treatment with antipsychotic medications.
Henderson
D C
DC
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Mass, USA. dchenderson@partners.org
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy*; D018570:Risk Assessment; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents